Please find enclosed Annual report for FY 2025-26

September 08, 2026 BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400001 Scrip Code: 511509 Dear Sir/Madam, Subject : Submission of Annual Report along with Notice of 39th Annual General Meeting (AGM) of the Company for financial year 2025-2026 Pursuant to Regulation 30 & 34 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, please find enclosed herewith the Notice convening 39th Annual General Meeting (AGM) of the Members of Vivo Bio Tech Limited (‘the Company”) scheduled to be held on Wednesday, September 30, 2026, at 03.00 P.M. (IST) through Video Conferencing (VC)/Other Audio-Visual Means (OAVM) and Annual Report for the financial year 2025-2026. The same is also made available on the website of the Company at www.vivobio.com. Further, in terms of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management & Administration) Rules, 2014 and Regulation 44 of SEBI (LODR) Regulations, 2015, the Company will provide to its members the facility to cast their vote(s) on all resolutions set forth in the Notice by electronic means ("e-voting") or voting through electronic means during the AGM, on the businesses specified in the Notice convening the 39th AGM of the Company. This is for your information and records. Thanking You, For Vivo Bio Tech Limited Bhavish Vijayvargiya Company Secretary & Compliance Officer M.No: A77631 Encl. as above REPORT NAVIGATOR CORPORATE NARRATIVE 04 12 23 CORPORATE OVERVIEW OUR BUSINESS OUR PEOPLE 25 30 35 BUSINESS PERFORMANCE INDUSTRY OUTLOOK ENTERPRISE RISK & RESPONSIBILITY MANAGEMENT DISCUSSION & ANALYSIS STATUTORY REPORTING 52 72 GOVERNANCE & STATUTORY NOTICE OF ANNUAL GENERAL MEETING BOARD’S REPORT REPORTING 119 151 176 STANDALONE FINANCIAL STATEMENTS CONSOLIDATED FINANCIAL STATEMENTS CORPORATE INFORMATION LEADERSHIP STATEMENT Dear Shareholders, FY 2025–26 was a defining year for Vivo Bio Tech. A major milestone during the year was achieving GLP recognition for our canine facility, which strengthened our credibility as a reliable preclinical research partner and enhanced our ability to support regulated repeated-dose toxicity and pharmacokinetic studies for pharmaceutical and biotech clients. We imported breeder Beagle dogs from Ridglan Farms, Inc., USA, and significantly enhanced our scientific and operational capabilities by recruiting additional experienced technical personnel and investing in critical analytical and research infrastructure, including HPLC, LC-MS/MS, flow cytometry and multimode reader platforms. Key achievements of the year • Expanded toxicology and analytical chemistry infrastructure across multiple specialised domains. • Enhanced bioanalytical capacity with four high-performance LC-MS/MS systems to support small- and large- molecule analysis. • Initiated dog GLP toxicology studies for USA clients. • Strengthened the CRO business with an additional team and focused business-development efforts, resulting in the acquisition of multiple projects across diverse product lines and a stronger, more sustainable project pipeline following the post-COVID recovery. Over the next two to three years, our objective is to convert investments in people, technology, analytical capabilities and large- animal infrastructure into sustainable CRO revenue growth. We will focus on higher-value GLP-compliant programmes, deeper relationships with pharmaceutical and multinational clients, and planned expansion of swine and non-human primate (NHP) facilities — positioning Vivo as a long-term preclinical research partner across increasingly complex stages of product development. Alongside expansion, we will continue to invest in the foundations that sustain trust: skilled scientific leadership, rigorous quality systems, responsible animal welfare practices and dependable client communication. These disciplines are essential to maintaining regulatory credibility, earning repeat business and ensuring that growth is resilient, responsible and aligned with the long-term interests of all stakeholders. “Importantly, growth will be pursued with discipline. As a listed company, we recognise that scientific capability must translate into consistent execution, higher utilisation, stronger cash generation and transparent governance. Our priorities therefore remain clear: deepen client trust, improve project delivery, convert installed capacity into sustainable revenue and deploy capital selectively where it strengthens long-term competitiveness” Satyanarayana Vedula Director VISION, MISSION & VALUES OUR VISION To be the most preferred global preclinical research and toxicology service provider, empowering partners to discover and bring innovative, life-saving medicines to patients worldwide. MISSION — HOW WE DELIVER 01 02 OPERATIONAL EXCELLENCE SCIENTIFIC INNOVATION Achieve the highest level of efficiency across all research Maintain complete commitment to scientific rigor, advanced activities, with quality, data integrity and compliance as core technology and modern life-science capabilities to accelerate foundations. client drug-discovery programmes. 03 04 ETHICAL STANDARDS CONTINUOUS GROWTH Uphold strict animal-welfare practices, regulatory compliance Constantly adapt to and implement cutting-edge advancements and corporate social responsibility for environmental protection. in medical science, life technology and artificial intelligence. CORE VALUES — WHAT GUIDES US 01 02 SCIENTIFIC INTEGRITY ETHICAL STEWARDSHIP Uncompromising commitment to reliable, reproducible and Highest standards of animal care, welfare and responsible regulatory-compliant data. research practices. 03 04 CLIENT PARTNERSHIP EXCELLENCE & QUALITY Tailored, collaborative execution aligned to every client's unique Continuous refinement of processes, infrastructure and technical developmental timeline. skill sets. PRINCIPAL STRATEGIC STRENGTHS 01 Regulatory credibility 02 Integrated capabilities 03 Infrastructure 05 Experienced and Competent Scientific 04 Capability/capacity 06 Cost Advantage team VIVO AT A GLANCE Vivo Bio Tech Limited (BSE: 511509), incorporated on 12 February 1987, is a Hyderabad-headquartered, full-service preclinical Contract Research Organization operating from Pregnapur Village, Gajwel Mandal, Siddipet District, Telangana – 502311. The Company delivers discovery, development, in vivo and in vitro toxicology, genetic toxicology, DMPK/bioanalytical, ecotoxicology and medical-device biocompatibility services to pharmaceutical, biotechnology, agrochemical, industrial-chemical, vaccine, adjuvant, cosmetics and medical-device clients worldwide under OECD GLP, AAALACi and CDSCO-recognised standards. AN INTEGRATED PLATFORM FOR DEPENDABLE EXECUTION Integrated execution model — Vivo combines in vivo, in vitro, analytical and bioanalytical capabilities with animal breeding and specialised models within a coordinated operating platform. This integration enables study programmes to move across scientific disciplines with fewer hand-offs, clearer accountability and continuity of data, quality oversight and reporting. Principal Revenue-Generating business lines • In vivo and in vitro toxicology • Genetic toxicology (in vivo and in vitro) • Pharmacology and efficacy studies • Analytical chemistry and bioanalytical • DMPK / ADME studies • Cell-culture studies services • Testing for pharmaceuticals, • Ecotoxicology (aquatic & terrestrial) • Regulatory / IND-enabling studies agrochemicals, medical devices, chemicals and cosmetics Industries & Segments Served Vivo's client base spans eleven industry segments, reflecting the breadth of its integrated preclinical and animal-model platform: • SPF Rodent Breeding • Industrial Chemicals / Bio-stimulants • Agrochemicals • Pharma / Vaccine Adjuvants • Biopharma • Cosmetics • Medical Devices • Custom Breeding Solutions • Lab / Custom Diet Supply • Preclinical CROs • Nutraceuticals CAPABILITY, CAPACITY, QUALITY, EQUIPMENT AND EXPERTISE Capabil [Showing first 8,000 characters — download PDF for full document]